奥美医疗：10月24日召开董事会会议

Group 1 - The core point of the article is that Aomei Medical (SZ 002950) held its 16th meeting of the third board of directors on October 24, 2025, to discuss the proposal for convening a shareholders' meeting [1] - For the first half of 2025, Aomei Medical's revenue composition was 94.13% from medical devices and 5.87% from other sources [1] - As of the time of reporting, Aomei Medical's market capitalization was 6.2 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]